Evotec completes Cyprotex acquisition

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/travellinglight)
(Image: iStock/travellinglight)

Related tags Preclinical contract research Contract research organization Evotec

Evotec AG has completed its previously announced acquisition of the preclinical contract research organization (CRO), Cyrotex.

Evotec announced its intent​ to acquire CRO in October of this year. Dr Wener Lanthaler, CEO, described the move as “a big step forward​,” during a conference call addressing the news.

The company is paying £55.7m in cash for the full share capital of Cyprotex – up slightly from the original £55.36m ($67.65) which the company offered to pay, as reported​ in October.

Cyprotex will continue to operate and serve its client base under its brand name “Cyprotex.”

Employees and capabilities will be integrated into Evotec’s global drug discovery group in order to leverage both companies’ partner networks and to identify further “commercial synergies​,” according to Evotec.

Evotec expects the Cyprotex business to add approximately €18 to €20m ($18.75 to $20.83m) in revenues in 2017.

Related news

Show more

Related products

show more

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us


View more